
Enzymatica Investor Relations Material
Latest events

Study Result
Enzymatica

Q2 2025
17 Jul, 2025

Q1 2025
29 Apr, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Enzymatica
Access all reports
Enzymatica AB, a life science company, develops and sells medical devices for infection-related diseases in Sweden and internationally. The company offers ColdZyme, an oral spray for the treatment of common cold; and ear spray for the treatment of otitis media that is primarily intended for infants and small children. Its products are based on its patented enzyme technology, which mimics the body's natural system for managing harmful bacteria. The company markets its products to pharmacies, audiologists, cancer centers, leukemia patients, surgeons, and ENT departments; and online.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
ENZY
Country
🇸🇪 Sweden